Drugs for Osteoporosis — MCQs
A 60-year-old elderly female with a previous history of a Colles fracture is now complaining of backache. Which of the following statements regarding the treatment of this patient is incorrect?
Which of the following is not true regarding estrogen use in postmenopausal osteoporosis management?
Osteoporosis is seen in all the following except
Which of the following is the first-line management for postmenopausal women with osteoporosis?
What is the first-line drug for post-menopausal osteoporosis?
Which of the following is recombinant parathyroid hormone (rPTH) used in osteoporosis treatment?
Which of the following anti-diabetic drugs is associated with increased risk of UTI?
What is the first-line drug for osteoporosis in postmenopausal women?
Drug of choice for post menopausal osteoporosis is
The success of estrogen and estrogen-like drugs in combating osteoporosis in postmenopausal women may indicate that estrogen:
Drugs for Osteoporosis Indian Medical PG Practice Questions and MCQs
Question 1: A 60-year-old elderly female with a previous history of a Colles fracture is now complaining of backache. Which of the following statements regarding the treatment of this patient is incorrect?
- A. Oral vitamin D3 is given along with oral calcium
- B. Teriparatide should be started before supplementing bisphosphonates (Correct Answer)
- C. Calcium requirement is 1200 mg per day
- D. Bisphosphonates can be given for 3-5 years depending on patient response and risk factors
Explanation: ***Teriparatide should be started before supplementing bisphosphonates*** - This statement is incorrect because **bisphosphonates are typically the first-line treatment** for osteoporosis, especially in patients with a history of fragility fractures like a Colles fracture. - **Teriparatide**, an anabolic agent, is usually reserved for patients with very severe osteoporosis, those who have failed bisphosphonate therapy, or those with highly accelerated bone loss. *Oral vitamin D3 is given along with oral calcium* - This is a routine and **correct practice in osteoporosis management** as calcium and vitamin D are essential for bone health. - **Vitamin D** aids in calcium absorption from the gut, and both are crucial for bone mineralization and density. *Calcium requirement is 1200 mg per day* - The recommended daily **calcium intake for postmenopausal women** and elderly individuals with osteoporosis is typically around 1200 mg. - This amount helps to maintain skeletal health and reduce the risk of fractures. *Bisphosphonates can be given for 3-5 years depending on patient response and risk factors* - This statement is correct, as **bisphosphonates are commonly prescribed for 3-5 years** to reduce fracture risk in osteoporosis. - A **"drug holiday"** may be considered after this period, depending on the patient's fracture risk and bone mineral density.
Question 2: Which of the following is not true regarding estrogen use in postmenopausal osteoporosis management?
- A. Improves bone density
- B. Lowers breast cancer risk (Correct Answer)
- C. Increases thromboembolism risk
- D. May cause endometrial hyperplasia
Explanation: ***Lowers breast cancer risk*** - Estrogen use, particularly **combined estrogen-progestin therapy**, actually **increases** the risk of breast cancer, rather than lowering it [1]. - This increased risk is a significant concern and a primary reason why estrogen therapy is not a first-line treatment for osteoporosis [1]. *Improves bone density* - Estrogen therapy is known to **prevent bone loss** and **increase bone mineral density** in postmenopausal women by inhibiting osteoclast activity [1]. - This effect is beneficial in reducing the risk of osteoporotic fractures [1], [2]. *Increases thromboembolism risk* - Estrogen therapy significantly **increases the risk of venous thromboembolism (VTE)**, including deep vein thrombosis and pulmonary embolism. - This is a well-established adverse effect and a contraindication in women with a history of thrombotic events. *May cause endometrial hyperplasia* - Unopposed estrogen therapy can **stimulate endometrial proliferation**, leading to **endometrial hyperplasia** and an increased risk of endometrial cancer. - This is why progestin is typically added to estrogen therapy in women with an intact uterus.
Question 3: Osteoporosis is seen in all the following except
- A. Steroid therapy
- B. Rheumatoid arthritis
- C. Thyrotoxicosis
- D. Hypoparathyroidism (Correct Answer)
Explanation: ***Hypoparathyroidism*** - Hypoparathyroidism leads to low levels of **parathyroid hormone (PTH)**, which causes **hypocalcemia** and **hyperphosphatemia**. - This condition is associated with **increased bone density** and sometimes osteosclerosis, rather than osteoporosis. *Steroid therapy* - **Glucocorticoids** inhibit osteoblast function and promote osteoclast activity, leading to **bone demineralization** and osteoporosis [1]. - This is a common cause of secondary osteoporosis, especially with long-term systemic use [1]. *Rheumatoid arthritis* - **Chronic inflammation** in rheumatoid arthritis contributes to generalized bone loss and osteoporosis [1]. - Additionally, patients often receive **glucocorticoid treatment**, which further exacerbates bone loss [1]. *Thyrotoxicosis* - **Excessive thyroid hormone** directly stimulates bone remodeling, increasing both bone formation and resorption. - However, the increase in **resorption outpaces formation**, leading to overall bone loss and a higher risk of osteoporosis.
Question 4: Which of the following is the first-line management for postmenopausal women with osteoporosis?
- A. Calcitonin
- B. Raloxifene
- C. Tamoxifen
- D. Bisphosphonates (Correct Answer)
Explanation: ***Bisphosphonates*** - **Bisphosphonates** are the **first-line therapy** for postmenopausal osteoporosis due to their proven efficacy in reducing the risk of fragility fractures. - They work by **inhibiting osteoclast activity**, thereby decreasing bone resorption and increasing bone mineral density. *Calcitonin* - **Calcitonin** is a hormone that inhibits bone resorption, but its **anti-fracture efficacy is weaker** than bisphosphonates. - It is typically used as a **second-line agent** or for patients who cannot tolerate bisphosphonates, often for its analgesic effect in vertebral compression fractures. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that mimics estrogen's beneficial effects on bone. - While it helps prevent vertebral fractures, it is **less effective than bisphosphonates** at preventing non-vertebral fractures and carries a risk of venous thromboembolism. *Tamoxifen* - **Tamoxifen** is also a **SERM**, primarily used in the treatment of **estrogen receptor-positive breast cancer**. - While it has **estrogen-like effects on bone** and can improve bone density, it is not approved or routinely used for the primary management of osteoporosis due to its other systemic effects and risks.
Question 5: What is the first-line drug for post-menopausal osteoporosis?
- A. Raloxifene
- B. Calcitonin
- C. Bisphosphonates (Correct Answer)
- D. Oestrogen
Explanation: **Bisphosphonates** - **Bisphosphonates** are the **first-line therapy** for postmenopausal osteoporosis due to their proven efficacy in reducing the risk of fragility fractures. - They work by **inhibiting osteoclast activity**, thereby reducing bone resorption and increasing bone mineral density. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that can be used for osteoporosis prevention and treatment, but it is typically a second-line option, especially in women who cannot tolerate bisphosphonates or have an increased risk of breast cancer. - While it has a positive effect on bone density, its fracture-reduction efficacy is not as broad as bisphosphonates (e.g., it reduces vertebral fractures but has less consistent data on non-vertebral fractures). *Calcitonin* - **Calcitonin** is generally reserved for patients who cannot tolerate other therapies or for short-term use in acute vertebral fractures to help with pain relief. - Its efficacy in reducing fracture risk is **less robust** compared to bisphosphonates, and it is not considered a first-line agent. *Oestrogen* - **Estrogen (hormone replacement therapy)** was once a primary treatment but is now generally not recommended as first-line for osteoporosis due to concerns about increased risks of breast cancer, cardiovascular events, and stroke, particularly in older women. - It is typically reserved for women with significant menopausal symptoms for whom other therapies are contraindicated or ineffective, and for the shortest duration possible.
Question 6: Which of the following is recombinant parathyroid hormone (rPTH) used in osteoporosis treatment?
- A. Teriparatide (Correct Answer)
- B. Calcipotriol
- C. Denosumab
- D. Calcitriol
Explanation: ***Teriparatide*** - **Teriparatide** is a **recombinant human parathyroid hormone (rPTH)**. It is an **anabolic agent** used in osteoporosis treatment. - Unlike antiresorptive agents, teriparatide **stimulates osteoblastic activity** and new bone formation, leading to increased bone mineral density and reduced fracture risk. *Calcipotriol* - **Calcipotriol** is a vitamin D analog primarily used topically for the treatment of **psoriasis**. - It works by regulating cell proliferation and differentiation in the skin, and is **not used for osteoporosis**. *Denosumab* - **Denosumab** is a **monoclonal antibody** that targets RANKL, inhibiting osteoclast formation and function, thus **reducing bone resorption**. - While it is a treatment for osteoporosis, it is an **antiresorptive agent**, not a recombinant parathyroid hormone. *Calcitriol* - **Calcitriol** is the **active form of vitamin D** and is used to treat conditions like hypocalcemia and metabolic bone disease associated with kidney failure. - It primarily helps with **calcium absorption** and bone mineralization, but it is not a recombinant parathyroid hormone and is not a primary anabolic treatment for osteoporosis.
Question 7: Which of the following anti-diabetic drugs is associated with increased risk of UTI?
- A. Dapagliflozin (Correct Answer)
- B. Pioglitazone
- C. Metformin
- D. Sitagliptin
Explanation: ***Dapagliflozin*** - **Dapagliflozin** is a **sodium-glucose cotransporter-2 (SGLT2) inhibitor** that works by increasing glucose excretion in the urine. - This increased urinary glucose provides a favorable environment for bacterial growth, leading to a higher risk of **urinary tract infections (UTIs)** and **genital mycotic infections**. *Pioglitazone* - **Pioglitazone** is a **thiazolidinedione** that improves insulin sensitivity in peripheral tissues. - Its primary side effects include **fluid retention**, **weight gain**, and increased risk of **bone fractures** and **heart failure**, not UTIs. *Metformin* - **Metformin** is a **biguanide** that reduces hepatic glucose production and improves insulin sensitivity. - Its most common side effects are **gastrointestinal disturbances** like nausea, diarrhea, and abdominal pain, and it does not typically increase the risk of UTIs. *Sitagliptin* - **Sitagliptin** is a **dipeptidyl peptidase-4 (DPP-4) inhibitor** that enhances endogenous incretin hormones, leading to increased insulin release and reduced glucagon secretion. - It is generally well-tolerated, with side effects that can include **nasopharyngitis** and headache, but it is not associated with an increased risk of UTIs.
Question 8: What is the first-line drug for osteoporosis in postmenopausal women?
- A. OCP
- B. Bisphosphonates (Correct Answer)
- C. Raloxifene
- D. Strontium
Explanation: ***Bisphosphonates*** - **Bisphosphonates** are the **first-line treatment** for osteoporosis due to their proven efficacy in reducing fracture risk by inhibiting osteoclast activity. - They bind to bone mineral and are internalized by osteoclasts, leading to their **apoptosis** and decreased bone resorption. *OCP* - **Oral contraceptives (OCP)** are not used for treating established osteoporosis; they may have a minor protective effect against bone loss in premenopausal women but are not a primary therapeutic agent postmenopause. - OCPs primarily contain **estrogen and/or progestin** and are used for contraception and managing menstrual irregularities. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that can be used for osteoporosis prevention and treatment, especially if there's a concern for breast cancer, but it is typically a second-line option. - Although it mimics estrogen's beneficial effects on bone, it does not have the same overall fracture reduction efficacy as bisphosphonates and can increase the risk of **venous thromboembolism**. *Strontium* - **Strontium ranelate** is an anti-osteoporotic agent that both inhibits bone resorption and promotes bone formation. - Its use has been limited due to concerns about serious side effects, including an increased risk of **cardiovascular events** and **venous thromboembolism**, making it a less favored option compared to bisphosphonates.
Question 9: Drug of choice for post menopausal osteoporosis is
- A. Bisphosphonates (Correct Answer)
- B. Estrogen
- C. Thyroxine
- D. Teriparatide
Explanation: ***Bisphosphonates*** - **Bisphosphonates** are considered the **first-line therapy** for established postmenopausal osteoporosis due to their proven efficacy in reducing the risk of vertebral and non-vertebral fractures. - They work by **inhibiting osteoclast activity**, thereby decreasing bone resorption and increasing bone mineral density. *Estrogen* - While **estrogen therapy** can prevent osteoporosis, it is generally not the first-line treatment due to potential risks like increased risk of **breast cancer**, **stroke**, and **venous thromboembolism**. - It is typically reserved for women with severe menopausal symptoms who also require osteoporosis prevention, and often used at the **lowest effective dose for the shortest duration**. *Thyroxine* - **Thyroxine** is a hormone used primarily to treat **hypothyroidism**, a condition where the thyroid gland doesn't produce enough thyroid hormone. - It is **not indicated for the treatment of osteoporosis** and can even worsen bone loss if given in excessive doses, leading to iatrogenic hyperthyroidism. *Teriparatide* - **Teriparatide** is an **anabolic agent** that stimulates new bone formation, making it a powerful option for severe osteoporosis or those who have failed other therapies. - However, it is an injectable medication with a **limited treatment duration** (typically 2 years) and is generally reserved for patients with a **high fracture risk** rather than being the initial drug of choice for all postmenopausal osteoporosis.
Question 10: The success of estrogen and estrogen-like drugs in combating osteoporosis in postmenopausal women may indicate that estrogen:
- A. Increases the activity of bone-resorbing cells
- B. Decreases the activity of bone-resorbing cells (Correct Answer)
- C. Prevents the mineralization of bone during turnover
- D. Reduces the activity of bone-forming cells
Explanation: ***Decreases the activity of bone-resorbing cells*** - **Estrogen** plays a crucial role in maintaining **bone density** by inhibiting the activity of **osteoclasts**, which are the cells responsible for **bone resorption**. - In postmenopausal women, the decline in estrogen levels leads to increased osteoclast activity and accelerated **bone loss**, hence the effectiveness of estrogen therapy. *Increases the activity of bone-resorbing cells* - An increase in **bone-resorbing cell** (osteoclast) activity would lead to further **bone loss** and exacerbate osteoporosis, contrary to the observed therapeutic effect of estrogen. - Estrogen's protective role in **bone health** is primarily through its inhibitory effect on osteoclasts. *Prevents the mineralization of bone during turnover* - This option describes a process that would lead to **osteomalacia** or **rickets**, where new bone matrix fails to mineralize adequately. - Estrogen's action is not primarily on mineralization but on the **balance between bone formation and resorption**. *Reduces the activity of bone-forming cells* - Reducing the activity of **bone-forming cells** (osteoblasts) would also lead to reduced bone density and worsen osteoporosis. - While estrogen has complex effects, its main therapeutic benefit in osteoporosis is to **slow down bone breakdown**, not to reduce bone formation.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free